Skip to content

Reproductive Health Survivorship Care Plan

Intervening on Reproductive Health in Young Breast Cancer Survivors

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02667626
Acronym
SCPR
Enrollment
182
Registered
2016-01-29
Start date
2015-03-25
Completion date
2019-01-24
Last updated
2020-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Contraception, Fertility, Hot Flashes, Sexual Dysfunction

Keywords

Breast cancer survivor, Cancer survivorship, Survivorship care plan, Vaginal dryness, Vulvovaginal atrophy, Vasomotor symptom, Infertility, Family planning

Brief summary

The investigators propose to test the efficacy of the Reproductive Health Survivorship Care Plan (SCP-R), a novel survivorship care tool to meet the reproductive health needs of young breast cancer survivors (YBCS). Most YBCS undergo chemotherapy and/or endocrine therapy, treatments that impair ovarian function and result in significant reproductive health late effects. These late effects include symptoms of estrogen deprivation such as hot flashes, fertility concerns, limited contraception options and sexual problems. Together they have a major, negative impact on quality of life. Despite substantial research, treatment guidelines and clinical expertise on these issues, most YBCS and their healthcare providers have limited guidance on how best to manage these reproductive health late effects. The research team has generated a practical, accessible, evidence-based reproductive health survivorship care plan (the SCP-R) for YBCS and their providers to address this deficit in survivorship care. This clinical trial will test if YBCS who receive the web-based SCP-R are more likely than controls to improve on at least one of these reproductive health issues: hot flashes, sexual health, fertility concerns, and contraception.

Detailed description

Participants may be recruited from throughout the United States, as all study activities may be done remotely. It is not necessary to live in San Diego or visit UC San Diego to participate in the study. YBCS who are interested in the study will be provided access to an online screening survey to determine eligibility. Eligible YBCS who consent to the study will be followed for 24 weeks. Following a one-week study run in, YBCS participants will be randomized to the SCPR intervention or control arms and receive the corresponding interventions. All YBCS participants will complete 3 study time points at enrollment, 12 and 24 weeks. At each time point, they will complete a web-based study questionnaire on medical and reproductive health. YBCS participants will also daily track their hot flashes via text messaging. YBCS participants will designate a healthcare provider with whom they would discuss reproductive health issues. Designated healthcare providers will be approached to participate in the study. Those providers who enroll will complete 2 study assessments at weeks 0 and 24. At each study time point, HCP will be assessed for preparedness on managing reproductive health issues by a web-based questionnaire.

Interventions

OTHERReproductive Health Survivorship Care Plan (SCPR)

The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes, fertility concerns, contraception practices, and sexual function. The intervention also includes additional web-based information and resource lists, text-based reproductive health and study adherence prompts.

OTHERControl

Web-based resource lists and text-based study adherence reminders

Sponsors

University of California, San Diego
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

Inclusion: * Breast cancer (Stages 0-III) diagnosis * Breast cancer diagnosis age ≤ 45 years * ≤ 5 years since breast cancer diagnosis * Current age 18 to 50 years * Completed treatment with surgery, radiation and chemotherapy (if applicable) * Able to read English * Able to consent to the study * Access to an Internet connection Exclusion: • Women who are pregnant at recruitment

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants With a 50% Decrease in Hot Flash ScoreBaseline and 24 weeks50% decrease in hot flash score. The hot flash score is calculated as the weighted sum of the number of hot flashes in each severity category multiplied by a severity-exclusive weight (1-mild, 2-moderate, 3-severe, 4-very severe). The minimum is 0 and there is no maximum. For example a woman can experience an unlimited number of hot flashes per day. Higher score indicates worse outcome.
Number of Participants With the Reproductive Concerns After Cancer Scale - Fertility Concerns Subscale Score <=324 weeksFertility concerns subscale score \<=3. Scores for the fertility subscale calculated by averaging responses (range 1-5) to the 3 subscale questions. The minimum score is 1, the maximum score is 5, Higher scores indicate worse outcome.
Number of Participants Using a WHO Class I or II Contraception24 weeksUse of World Health Organization Class I or II contraceptive methods (intrauterine devices, female sterilization, male partner sterilization, combined hormonal contraception, progestin implants or injections)
Number of Participants With a 50% Decrease in Vulvovaginal Atrophy ScoreBaseline and 24 weeksThe Vulvovaginal Atrophy Score is a 4-item scale on vaginal dryness, soreness, irritation and dyspareunia experienced in the prior 4 weeks\]. Each item has a 4-point Likert scale response (0-none, 1-mild, 2-moderate, 3-severe). The scale is summarized by averaging responses, with higher scores indicating a greater level of vaginal atrophy.

Secondary

MeasureTime frameDescription
Healthcare Provider Preparedness Scale24 weeksChange in score

Other

MeasureTime frameDescription
Depression (PHQ-8)12 and 24 weeksChange in score
Menopause Quality of Life (MENQOL)12 and 24 weeksChange in score
Social Support (MOS Social Support)12 and 24 weeksChange in score
Insomnia Scale12 and 24 weeksChange in score
Female Sexual Function Inventory12 and 24 weeksChange in score
Confidence for Managing Reproductive Health Issues Scale12 and 24 weeksChange in score

Countries

United States

Participant flow

Participants by arm

ArmCount
SCPR Intervention
Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information, including resource lists of helpful websites, followed by regular reproductive health prompts and study adherence reminders for 24 weeks. Reproductive Health Survivorship Care Plan (SCPR): The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes, fertility concerns, contraception practices, and sexual function. The intervention also includes additional web-based information and resource lists, text-based reproductive health and study adherence prompts.
86
Control
Young breast cancer participants randomized to the waitlist control arm will receive access to the web-based resources and study adherence reminders. At completion of the 24 weeks of follow up, they will have access to their SCPR. Control: Web-based resource lists and text-based study adherence reminders
96
Total182

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyWithdrawal by Subject01

Baseline characteristics

CharacteristicSCPR InterventionControlTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
86 Participants96 Participants182 Participants
Age, Continuous40.3 years
STANDARD_DEVIATION 5.9
39.6 years
STANDARD_DEVIATION 6
40.0 years
STANDARD_DEVIATION 5.9
Ethnicity (NIH/OMB)
Hispanic or Latino
4 Participants6 Participants10 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
82 Participants90 Participants172 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
1 Participants7 Participants8 Participants
Race (NIH/OMB)
More than one race
8 Participants9 Participants17 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
77 Participants80 Participants157 Participants
Region of Enrollment
United States
86 participants96 participants182 participants
Sex: Female, Male
Female
86 Participants96 Participants182 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 860 / 96
other
Total, other adverse events
0 / 860 / 96
serious
Total, serious adverse events
0 / 860 / 96

Outcome results

Primary

Number of Participants Using a WHO Class I or II Contraception

Use of World Health Organization Class I or II contraceptive methods (intrauterine devices, female sterilization, male partner sterilization, combined hormonal contraception, progestin implants or injections)

Time frame: 24 weeks

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
SCPR InterventionNumber of Participants Using a WHO Class I or II Contraception43 Participants
ControlNumber of Participants Using a WHO Class I or II Contraception41 Participants
Primary

Number of Participants With a 50% Decrease in Hot Flash Score

50% decrease in hot flash score. The hot flash score is calculated as the weighted sum of the number of hot flashes in each severity category multiplied by a severity-exclusive weight (1-mild, 2-moderate, 3-severe, 4-very severe). The minimum is 0 and there is no maximum. For example a woman can experience an unlimited number of hot flashes per day. Higher score indicates worse outcome.

Time frame: Baseline and 24 weeks

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
SCPR InterventionNumber of Participants With a 50% Decrease in Hot Flash Score50 Participants
ControlNumber of Participants With a 50% Decrease in Hot Flash Score53 Participants
Primary

Number of Participants With a 50% Decrease in Vulvovaginal Atrophy Score

The Vulvovaginal Atrophy Score is a 4-item scale on vaginal dryness, soreness, irritation and dyspareunia experienced in the prior 4 weeks\]. Each item has a 4-point Likert scale response (0-none, 1-mild, 2-moderate, 3-severe). The scale is summarized by averaging responses, with higher scores indicating a greater level of vaginal atrophy.

Time frame: Baseline and 24 weeks

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
SCPR InterventionNumber of Participants With a 50% Decrease in Vulvovaginal Atrophy Score37 Participants
ControlNumber of Participants With a 50% Decrease in Vulvovaginal Atrophy Score39 Participants
Primary

Number of Participants With the Reproductive Concerns After Cancer Scale - Fertility Concerns Subscale Score <=3

Fertility concerns subscale score \<=3. Scores for the fertility subscale calculated by averaging responses (range 1-5) to the 3 subscale questions. The minimum score is 1, the maximum score is 5, Higher scores indicate worse outcome.

Time frame: 24 weeks

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
SCPR InterventionNumber of Participants With the Reproductive Concerns After Cancer Scale - Fertility Concerns Subscale Score <=324 Participants
ControlNumber of Participants With the Reproductive Concerns After Cancer Scale - Fertility Concerns Subscale Score <=314 Participants
Secondary

Healthcare Provider Preparedness Scale

Change in score

Time frame: 24 weeks

Population: Data were not collected

Other Pre-specified

Confidence for Managing Reproductive Health Issues Scale

Change in score

Time frame: 12 and 24 weeks

Other Pre-specified

Depression (PHQ-8)

Change in score

Time frame: 12 and 24 weeks

Other Pre-specified

Female Sexual Function Inventory

Change in score

Time frame: 12 and 24 weeks

Other Pre-specified

Insomnia Scale

Change in score

Time frame: 12 and 24 weeks

Other Pre-specified

Menopause Quality of Life (MENQOL)

Change in score

Time frame: 12 and 24 weeks

Other Pre-specified

Social Support (MOS Social Support)

Change in score

Time frame: 12 and 24 weeks

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026